In our workshop cases, molecular characterization of both components of these cases provided evidence of the clonal relationship between ECD and the concurrent or evolving myeloid neoplasms, ranging from a single (BRAFV600E or NRASQ61R) to multiple shared mutations (ASXL1, BRAFV600E, TET2, and U2AF1 or BRAFV600E, SRSF2, and TET2, respectively) in 2 cases each. This evidence concerns the gene TET2 and myeloid neoplasm.